nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

22.02.2018 | Focussed Research Review

Mucosa-associated invariant T cells in malignancies: a faithful friend or formidable foe?

verfasst von: S. M. Mansour Haeryfar, Christopher R. Shaler, Patrick T. Rudak

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Mucosa-associated invariant T (MAIT) cells are a subset of innate-like T lymphocytes known for their ability to respond to MHC-related protein 1 (MR1)-restricted stimuli and select cytokine signals. They are abundant in humans and especially enriched in mucosal layers, common sites of neoplastic transformation. MAIT cells have been found within primary and metastatic tumors. However, whether they promote malignancy or contribute to anticancer immunity is unclear. On the one hand, MAIT cells produce IL-17A in certain locations and under certain circumstances, which could in turn facilitate neoangiogenesis, intratumoral accumulation of immunosuppressive cell populations, and cancer progression. On the other hand, they can express a potent arsenal of cytotoxic effector molecules, NKG2D and IFN-γ, all of which have established roles in cancer immune surveillance. In this review, we highlight MAIT cells’ characteristics as they might pertain to cancer initiation, progression, or control. We discuss recent findings, including our own, that link MAIT cells to cancer, with a focus on colorectal carcinoma, as well as some of the outstanding questions in this active area of research. Finally, we provide a hypothetical picture in which MAIT cells constitute attractive targets in cancer immunotherapy.

Porcelli S, Yockey CE, Brenner MB, Balk SP (1993) Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med 178(1):1–16CrossRefPubMed

Lantz O, Bendelac A (1994) An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4 + and CD4-8- T cells in mice and humans. J Exp Med 180(3):1097–1106CrossRefPubMed

Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H, Bendelac A, Bonneville M, Lantz O (1999) An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. J Exp Med 189(12):1907–1921CrossRefPubMedPubMedCentral

Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, Affaticati P, Gilfillan S, Lantz O (2003) Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422(6928):164–169. https://doi.org/10.1038/nature01433 CrossRefPubMed

Yamaguchi H, Hirai M, Kurosawa Y, Hashimoto K (1997) A highly conserved major histocompatibility complex class I-related gene in mammals. Biochem Biophys Res Commun 238(3):697–702. https://doi.org/10.1006/bbrc.1997.7379 CrossRefPubMed

Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, Williamson NA, Purcell AW, Dudek NL, McConville MJ, O’Hair RA, Khairallah GN, Godfrey DI, Fairlie DP, Rossjohn J, McCluskey J (2012) MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491(7426):717–723. https://doi.org/10.1038/nature11605 CrossRefPubMed

Seach N, Guerri L, Le Bourhis L, Mburu Y, Cui Y, Bessoles S, Soudais C, Lantz O (2013) Double-positive thymocytes select mucosal-associated invariant T cells. J Immunol 191(12):6002–6009. https://doi.org/10.4049/jimmunol.1301212 CrossRefPubMed

Koay HF, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF, Russ BE, Nold-Petry CA, Nold MF, Bedoui S, Chen Z, Corbett AJ, Eckle SB, Meehan B, d’Udekem Y, Konstantinov IE, Lappas M, Liu L, Goodnow CC, Fairlie DP, Rossjohn J, Chong MM, Kedzierska K, Berzins SP, Belz GT, McCluskey J, Uldrich AP, Godfrey DI, Pellicci DG (2016) A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. Nat Immunol 17(11):1300–1311. https://doi.org/10.1038/ni.3565 CrossRefPubMed

Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D, Milder M, Le Bourhis L, Soudais C, Treiner E, Lantz O (2011) Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117(4):1250–1259. https://doi.org/10.1182/blood-2010-08-303339 CrossRefPubMed

10.

Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, Lee KH, Gehring AJ, De Libero G, Bertoletti A (2013) IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol 190(7):3142–3152. https://doi.org/10.4049/jimmunol.1203218 CrossRefPubMed

11.

Rahimpour A, Koay HF, Enders A, Clanchy R, Eckle SB, Meehan B, Chen Z, Whittle B, Liu L, Fairlie DP, Goodnow CC, McCluskey J, Rossjohn J, Uldrich AP, Pellicci DG, Godfrey DI (2015) Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers. J Exp Med 212(7):1095–1108. https://doi.org/10.1084/jem.20142110 CrossRefPubMedPubMedCentral

12.

Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Chen Z, Eckle SB, Uldrich AP, Birkinshaw RW, Patel O, Kostenko L, Meehan B, Kedzierska K, Liu L, Fairlie DP, Hansen TH, Godfrey DI, Rossjohn J, McCluskey J, Kjer-Nielsen L (2013) Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med 210(11):2305–2320. https://doi.org/10.1084/jem.20130958 CrossRefPubMedPubMedCentral

13.

Corbett AJ, Eckle SB, Birkinshaw RW, Liu L, Patel O, Mahony J, Chen Z, Reantragoon R, Meehan B, Cao H, Williamson NA, Strugnell RA, Van Sinderen D, Mak JY, Fairlie DP, Kjer-Nielsen L, Rossjohn J, McCluskey J (2014) T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature 509(7500):361–365. https://doi.org/10.1038/nature13160 CrossRefPubMed

14.

Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, de Lara C, Mettke E, Kurioka A, Hansen TH, Klenerman P, Willberg CB (2014) CD161 + + CD8 + T cells, including the MAIT cell subset, are specifically activated by IL-12 + IL-18 in a TCR-independent manner. Eur J Immunol 44(1):195–203. https://doi.org/10.1002/eji.201343509 CrossRefPubMed

15.

Salou M, Franciszkiewicz K, Lantz O (2017) MAIT cells in infectious diseases. Curr Opin Immunol 48:7–14. https://doi.org/10.1016/j.coi.2017.07.009 CrossRefPubMed

16.

van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, de Lara C, Cole S, Vasanawathana S, Limpitikul W, Malasit P, Young D, Denney L, consortium S-H, Moore, Fabris MD, Giordani P, Oo MT, Laidlaw YH, Dustin SM, Ho LB, Thompson LP, Ramamurthy FM, Mongkolsapaya N, Willberg J, Screaton CB, Klenerman GR P (2016) MAIT cells are activated during human viral infections. Nat Commun 7:11653. https://doi.org/10.1038/ncomms11653 CrossRefPubMedPubMedCentral

17.

Loh L, Wang Z, Sant S, Koutsakos M, Jegaskanda S, Corbett AJ, Liu L, Fairlie DP, Crowe J, Rossjohn J, Xu J, Doherty PC, McCluskey J, Kedzierska K (2016) Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation. Proc Natl Acad Sci USA 113(36):10133–10138. https://doi.org/10.1073/pnas.1610750113 CrossRefPubMedPubMedCentral

18.

Sattler A, Dang-Heine C, Reinke P, Babel N (2015) IL-15 dependent induction of IL-18 secretion as a feedback mechanism controlling human MAIT-cell effector functions. Eur J Immunol 45(8):2286–2298. https://doi.org/10.1002/eji.201445313 CrossRefPubMed

19.

Leeansyah E, Svard J, Dias J, Buggert M, Nystrom J, Quigley MF, Moll M, Sonnerborg A, Nowak P, Sandberg JK (2015) Arming of MAIT cell cytolytic antimicrobial activity is induced by IL-7 and defective in HIV-1 infection. PLoS Pathog 11(8):e1005072. https://doi.org/10.1371/journal.ppat.1005072 CrossRefPubMedPubMedCentral

20.

Spaan M, Hullegie SJ, Beudeker BJ, Kreefft K, van Oord GW, Groothuismink ZM, van Tilborg M, Rijnders B, de Knegt RJ, Claassen MA, Boonstra A (2016) Frequencies of circulating MAIT Cells are diminished in chronic HCV, HIV and HCV/HIV co-infection and do not recover during therapy. PLoS ONE 11(7):e0159243. https://doi.org/10.1371/journal.pone.0159243 CrossRefPubMedPubMedCentral

21.

Shaler CR, Choi J, Rudak PT, Memarnejadian A, Szabo PA, Tun-Abraham ME, Rossjohn J, Corbett AJ, McCluskey J, McCormick JK, Lantz O, Hernandez-Alejandro R, Haeryfar SMM (2017) MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: defining a novel mechanism of superantigen-induced immunopathology and immunosuppression. PLoS Biol 15(6):e2001930. https://doi.org/10.1371/journal.pbio.2001930 CrossRefPubMedPubMedCentral

22.

Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, Winata E, Swarbrick GM, Chua WJ, Yu YY, Lantz O, Cook MS, Null MD, Jacoby DB, Harriff MJ, Lewinsohn DA, Hansen TH, Lewinsohn DM (2010) Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 8(6):e1000407. https://doi.org/10.1371/journal.pbio.1000407 CrossRefPubMedPubMedCentral

23.

Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, Premel V, Core M, Sleurs D, Serriari NE, Treiner E, Hivroz C, Sansonetti P, Gougeon ML, Soudais C, Lantz O (2013) MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS Pathog 9(10):e1003681. https://doi.org/10.1371/journal.ppat.1003681 CrossRefPubMedPubMedCentral

24.

Kurioka A, Ussher JE, Cosgrove C, Clough C, Fergusson JR, Smith K, Kang YH, Walker LJ, Hansen TH, Willberg CB, Klenerman P (2015) MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets. Mucosal Immunol 8(2):429–440. https://doi.org/10.1038/mi.2014.81 CrossRefPubMed

25.

Dias J, Leeansyah E, Sandberg JK (2017) Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci USA 114(27):E5434–E5443. https://doi.org/10.1073/pnas.1705759114 CrossRef

26.

Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, Kiaf B, Beaudoin L, Da Silva J, Allatif O, Rossjohn J, Kjer-Nielsen L, McCluskey J, Ledoux S, Genser L, Torcivia A, Soudais C, Lantz O, Boitard C, Aron-Wisnewsky J, Larger E, Clement K, Lehuen A (2015) Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. J Clin Invest 125(4):1752–1762. https://doi.org/10.1172/JCI78941 CrossRefPubMedPubMedCentral

27.

Carolan E, Tobin LM, Mangan BA, Corrigan M, Gaoatswe G, Byrne G, Geoghegan J, Cody D, O’Connell J, Winter DC, Doherty DG, Lynch L, O’Shea D, Hogan AE (2015) Altered distribution and increased IL-17 production by mucosal-associated invariant T cells in adult and childhood obesity. J Immunol 194(12):5775–5780. https://doi.org/10.4049/jimmunol.1402945 CrossRefPubMed

28.

Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, Galon J (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71(4):1263–1271. https://doi.org/10.1158/0008-5472.CAN-10-2907 CrossRefPubMed

29.

Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z, Zhu B (2011) IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407(2):348–354. https://doi.org/10.1016/j.bbrc.2011.03.021 CrossRefPubMed

30.

Li Q, Han Y, Fei G, Guo Z, Ren T, Liu Z (2012) IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett 148(2):144–150. https://doi.org/10.1016/j.imlet.2012.10.011 CrossRefPubMed

31.

Zhong F, Cui D, Tao H, Du H, Xing C (2015) IL-17A-producing T cells and associated cytokines are involved in the progression of gastric cancer. Oncol Rep 34(5):2365–2374. https://doi.org/10.3892/or.2015.4246 CrossRefPubMed

32.

Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, Farah W, Limagne E, Ladoire S, Boidot R, Derangere V, Ghiringhelli F (2017) Immune classifications with cytotoxic CD8(+) and Th17 infiltrates are predictors of clinical prognosis in glioblastoma. Oncoimmunology 6(6):e1321186. https://doi.org/10.1080/2162402X.2017.1321186 CrossRefPubMedPubMedCentral

33.

Xie Z, Qu Y, Leng Y, Sun W, Ma S, Wei J, Hu J, Zhang X (2015) Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses. Drug Des Devel Ther 9:1679–1689. https://doi.org/10.2147/DDDT.S79431 CrossRefPubMedPubMedCentral

34.

Numasaki M, Lotze MT, Sasaki H (2004) Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 93(1):39–43. https://doi.org/10.1016/j.imlet.2004.01.014 CrossRefPubMed

35.

Takahashi H, Numasaki M, Lotze MT, Sasaki H (2005) Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 98(2):189–193. https://doi.org/10.1016/j.imlet.2004.11.012 CrossRefPubMed

36.

Huang Q, Duan L, Qian X, Fan J, Lv Z, Zhang X, Han J, Wu F, Guo M, Hu G, Du J, Chen C, Jin Y (2016) IL-17 promotes angiogenic factors IL-6, IL-8, and Vegf production via Stat1 in lung adenocarcinoma. Sci Rep 6:36551. https://doi.org/10.1038/srep36551 CrossRefPubMedPubMedCentral

37.

Kulig P, Burkhard S, Mikita-Geoffroy J, Croxford AL, Hovelmeyer N, Gyulveszi G, Gorzelanny C, Waisman A, Borsig L, Becher B (2016) IL17A-mediated endothelial breach promotes metastasis formation. Cancer Immunol Res 4(1):26–32. https://doi.org/10.1158/2326-6066.CIR-15-0154 CrossRefPubMed

38.

Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, Chen Z, Wang K, Zhang T, Xu J, Han Y, Zhang T, Wu X, Wang J, Gong W, Zheng S, Qiu F, Yan J, Huang J (2014) gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40(5):785–800. https://doi.org/10.1016/j.immuni.2014.03.013 CrossRefPubMedPubMedCentral

39.

Hu G, Wu P, Cheng P, Zhang Z, Wang Z, Yu X, Shao X, Wu D, Ye J, Zhang T, Wang X, Qiu F, Yan J, Huang J (2017) Tumor-infiltrating CD39(+)gammadeltaTregs are novel immunosuppressive T cells in human colorectal cancer. Oncoimmunology 6(2):e1277305. https://doi.org/10.1080/2162402X.2016.1277305 CrossRefPubMedPubMedCentral

40.

Liu L, Ge D, Ma L, Mei J, Liu S, Zhang Q, Ren F, Liao H, Pu Q, Wang T, You Z (2012) Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol 7(7):1091–1100. https://doi.org/10.1097/JTO.0b013e3182542752 CrossRefPubMedPubMedCentral

41.

Li Q, Liu L, Zhang Q, Liu S, Ge D, You Z (2014) Interleukin-17 indirectly promotes M2 macrophage differentiation through stimulation of COX-2/PGE2 pathway in the cancer cells. Cancer Res Treat 46(3):297–306. https://doi.org/10.4143/crt.2014.46.3.297 CrossRefPubMedPubMedCentral

42.

Peterfalvi A, Gomori E, Magyarlaki T, Pal J, Banati M, Javorhazy A, Szekeres-Bartho J, Szereday L, Illes Z (2008) Invariant Valpha7.2-Jalpha33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells. Int Immunol 20(12):1517–1525. https://doi.org/10.1093/intimm/dxn111 CrossRefPubMed

43.

Sundstrom P, Ahlmanner F, Akeus P, Sundquist M, Alsen S, Yrlid U, Borjesson L, Sjoling A, Gustavsson B, Wong SB, Quiding-Jarbrink M (2015) Human mucosa-associated invariant T cells accumulate in colon adenocarcinomas but produce reduced amounts of IFN-gamma. J Immunol 195(7):3472–3481. https://doi.org/10.4049/jimmunol.1500258 CrossRefPubMed

44.

Zabijak L, Attencourt C, Guignant C, Chatelain D, Marcelo P, Marolleau JP, Treiner E (2015) Increased tumor infiltration by mucosal-associated invariant T cells correlates with poor survival in colorectal cancer patients. Cancer Immunol Immunother 64(12):1601–1608. https://doi.org/10.1007/s00262-015-1764-7 CrossRefPubMed

45.

Ling L, Lin Y, Zheng W, Hong S, Tang X, Zhao P, Li M, Ni J, Li C, Wang L, Jiang Y (2016) Circulating and tumor-infiltrating mucosal associated invariant T (MAIT) cells in colorectal cancer patients. Sci Rep 6:20358. https://doi.org/10.1038/srep20358 CrossRefPubMedPubMedCentral

46.

Won EJ, Ju JK, Cho YN, Jin HM, Park KJ, Kim TJ, Kwon YS, Kee HJ, Kim JC, Kee SJ, Park YW (2016) Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer. Oncotarget 7(46):76274–76290. https://doi.org/10.18632/oncotarget.11187 CrossRefPubMedPubMedCentral

47.

Shaler CR, Tun-Abraham ME, Skaro AI, Khazaie K, Corbett AJ, Mele T, Hernandez-Alejandro R, Haeryfar SMM (2017) Mucosa-associated invariant T cells infiltrate hepatic metastases in patients with colorectal carcinoma but are rendered dysfunctional within and adjacent to tumor microenvironment. Cancer Immunol Immunother 66(12):1563–1575. https://doi.org/10.1007/s00262-017-2050-7 CrossRefPubMed

48.

Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, Chatelain D, Barre A, Nguyen-Khac E, Lantz O, Dupas JL, Treiner E (2014) Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin Exp Immunol 176(2):266–274. https://doi.org/10.1111/cei.12277 CrossRefPubMedPubMedCentral

49.

Haga K, Chiba A, Shibuya T, Osada T, Ishikawa D, Kodani T, Nomura O, Watanabe S, Miyake S (2016) MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis. J Gastroenterol Hepatol 31(5):965–972. https://doi.org/10.1111/jgh.13242 CrossRefPubMed

50.

Chehimi M, Vidal H, Eljaafari A (2017) Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. J Clin Med 6 (7). https://doi.org/10.3390/jcm6070068 CrossRefPubMedCentral

51.

Slattery ML, Lundgreen A, Bondurant KL, Wolff RK (2011) Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis 32(11):1660–1667. https://doi.org/10.1093/carcin/bgr189 CrossRefPubMedPubMedCentral

52.

Lu S, Pardini B, Cheng B, Naccarati A, Huhn S, Vymetalkova V, Vodickova L, Buchler T, Hemminki K, Vodicka P, Forsti A (2014) Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival. PLoS ONE 9(10):e111061. https://doi.org/10.1371/journal.pone.0111061 CrossRefPubMedPubMedCentral

53.

Wang L, Wang Y, Song Z, Chu J, Qu X (2015) Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. J Interferon Cytokine Res 35(4):273–280. https://doi.org/10.1089/jir.2014.0132 CrossRefPubMed

54.

Yuan L, Zhou C, Lu Y, Hong M, Zhang Z, Zhang Z, Chang Y, Zhang C, Li X (2015) IFN-gamma-mediated IRF1/miR-29b feedback loop suppresses colorectal cancer cell growth and metastasis by repressing IGF1. Cancer Lett 359(1):136–147. https://doi.org/10.1016/j.canlet.2015.01.003 CrossRefPubMed

55.

Reeves E, James E (2017) Antigen processing and immune regulation in the response to tumours. Immunology 150(1):16–24. https://doi.org/10.1111/imm.12675 CrossRefPubMed

56.

Chen W, Masterman KA, Basta S, Haeryfar SM, Dimopoulos N, Knowles B, Bennink JR, Yewdell JW (2004) Cross-priming of CD8 + T cells by viral and tumor antigens is a robust phenomenon. Eur J Immunol 34(1):194–199. https://doi.org/10.1002/eji.200324257 CrossRefPubMed

57.

Deauvieau F, Ollion V, Doffin AC, Achard C, Fonteneau JF, Verronese E, Durand I, Ghittoni R, Marvel J, Dezutter-Dambuyant C, Walzer T, Vie H, Perrot I, Goutagny N, Caux C, Valladeau-Guilemond J (2015) Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. Int J Cancer 136(5):1085–1094. https://doi.org/10.1002/ijc.29087 CrossRefPubMed

58.

Jeannin P, Duluc D, Delneste Y (2011) IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-gamma. Immunotherapy 3(4 Suppl):23–26. https://doi.org/10.2217/imt.11.30 CrossRefPubMed

59.

Sun T, Yang Y, Luo X, Cheng Y, Zhang M, Wang K, Ge C (2014) Inhibition of tumor angiogenesis by interferon-gamma by suppression of tumor-associated macrophage differentiation. Oncol Res 21(5):227–235. https://doi.org/10.3727/096504014X13890370410285 CrossRefPubMed

60.

Naganuma H, Sasaki A, Satoh E, Nagasaka M, Nakano S, Isoe S, Nukui H (1998) Down-regulation of transforming growth factor-beta and interleukin-10 secretion from malignant glioma cells by cytokines and anticancer drugs. J Neurooncol 39(3):227–236CrossRefPubMed

61.

Beatty GL, Paterson Y (2001) Regulation of tumor growth by IFN-gamma in cancer immunotherapy. Immunol Res 24(2):201–210. https://doi.org/10.1385/IR:24:2:201 CrossRefPubMed

62.

Sgadari C, Angiolillo AL, Tosato G (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87(9):3877–3882PubMed

63.

Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G, Lee WM (1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9(1):25–34CrossRefPubMed

64.

Bukowski RM, Rayman P, Molto L, Tannenbaum CS, Olencki T, Peereboom D, Tubbs R, McLain D, Budd GT, Griffin T, Novick A, Hamilton TA, Finke J (1999) Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin Cancer Res 5(10):2780–2789PubMed

65.

Lopez-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-Alvarez M, Gonzalez S (2015) NKG2D signaling in cancer immunosurveillance. Int J Cancer 136(8):1741–1750. https://doi.org/10.1002/ijc.28775 CrossRefPubMed

66.

McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I, Trowsdale J, Durrant LG (2009) NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 15(22):6993–7002. https://doi.org/10.1158/1078-0432.CCR-09-0991 CrossRefPubMedPubMedCentral

67.

Lanier LL (2015) NKG2D Receptor and its ligands in host defense. Cancer Immunol Res 3(6):575–582. https://doi.org/10.1158/2326-6066.CIR-15-0098 CrossRefPubMedPubMedCentral

68.

Brozova J, Karlova I, Novak J (2016) Analysis of the phenotype and function of the subpopulations of mucosal-associated invariant T cells. Scand J Immunol 84(4):245–251. https://doi.org/10.1111/sji.12467 CrossRefPubMed

69.

Mullbacher A, Lobigs M, Hla RT, Tran T, Stehle T, Simon MM (2002) Antigen-dependent release of IFN-gamma by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cell lysis. J Immunol 169(1):145–150CrossRefPubMed

70.

Lepore M, Kalinichenko A, Colone A, Paleja B, Singhal A, Tschumi A, Lee B, Poidinger M, Zolezzi F, Quagliata L, Sander P, Newell E, Bertoletti A, Terracciano L, De Libero G, Mori L (2014) Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRbeta repertoire. Nat Commun 5:3866. https://doi.org/10.1038/ncomms4866 CrossRefPubMed

71.

Kucharzik T, Lugering N, Winde G, Domschke W, Stoll R (1997) Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10. Clin Exp Immunol 110(2):296–302CrossRefPubMedPubMedCentral

72.

Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M, Levy E, Dusseaux M, Meyssonnier V, Premel V, Ngo C, Riteau B, Duban L, Robert D, Huang S, Rottman M, Soudais C, Lantz O (2010) Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 11(8):701–708. https://doi.org/10.1038/ni.1890 CrossRefPubMed

73.

Novak J, Dobrovolny J, Brozova J, Novakova L, Kozak T (2016) Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation. Clin Exp Med 16(4):529–537. https://doi.org/10.1007/s10238-015-0384-z CrossRefPubMed

74.

Soudais C, Samassa F, Sarkis M, Le Bourhis L, Bessoles S, Blanot D, Herve M, Schmidt F, Mengin-Lecreulx D, Lantz O (2015) In vitro and in vivo analysis of the gram-negative bacteria-derived riboflavin precursor derivatives activating mouse MAIT cells. J Immunol 194(10):4641–4649. https://doi.org/10.4049/jimmunol.1403224 CrossRefPubMed

75.

Mak JY, Xu W, Reid RC, Corbett AJ, Meehan BS, Wang H, Chen Z, Rossjohn J, McCluskey J, Liu L, Fairlie DP (2017) Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells. Nat Commun 8:14599. https://doi.org/10.1038/ncomms14599 CrossRefPubMedPubMedCentral

76.

Keller AN, Eckle SB, Xu W, Liu L, Hughes VA, Mak JY, Meehan BS, Pediongco T, Birkinshaw RW, Chen Z, Wang H, D’Souza C, Kjer-Nielsen L, Gherardin NA, Godfrey DI, Kostenko L, Corbett AJ, Purcell AW, Fairlie DP, McCluskey J, Rossjohn J (2017) Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. Nat Immunol 18(4):402–411. https://doi.org/10.1038/ni.3679 CrossRefPubMed

77.

Zaidi MR, Merlino G (2011) The two faces of interferon-gamma in cancer. Clin Cancer Res 17(19):6118–6124. https://doi.org/10.1158/1078-0432.CCR-11-0482 CrossRefPubMedPubMedCentral

78.

Kursunel MA, Esendagli G (2016) The untold story of IFN-gamma in cancer biology. Cytokine Growth Factor Rev 31:73–81. https://doi.org/10.1016/j.cytogfr.2016.07.005 CrossRefPubMed

79.

Meermeier EW, Laugel BF, Sewell AK, Corbett AJ, Rossjohn J, McCluskey J, Harriff MJ, Franks T, Gold MC, Lewinsohn DM (2016) Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens. Nat Commun 7:12506. https://doi.org/10.1038/ncomms12506 CrossRefPubMedPubMedCentral

80.

Cui Y, Franciszkiewicz K, Mburu YK, Mondot S, Le Bourhis L, Premel V, Martin E, Kachaner A, Duban L, Ingersoll MA, Rabot S, Jaubert J, De Villartay JP, Soudais C, Lantz O (2015) Mucosal-associated invariant T cell-rich congenic mouse strain allows functional evaluation. J Clin Invest 125(11):4171–4185. https://doi.org/10.1172/JCI82424 CrossRefPubMedPubMedCentral

81.

Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C, Premel V, Devys A, Moura IC, Tilloy F, Cherif S, Vera G, Latour S, Soudais C, Lantz O (2009) Stepwise development of MAIT cells in mouse and human. PLoS Biol 7(3):e54. https://doi.org/10.1371/journal.pbio.1000054 CrossRefPubMed

Titel: Mucosa-associated invariant T cells in malignancies: a faithful friend or formidable foe?
verfasst von: S. M. Mansour Haeryfar
Christopher R. Shaler
Patrick T. Rudak
Publikationsdatum: 22.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 12/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2132-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Mucosa-associated invariant T cells in malignancies: a faithful friend or formidable foe?

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

The role of CCR5 in directing the mobilization and biological function of CD11b+Gr1+Ly6Clow polymorphonuclear myeloid cells in cancer

Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)

Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment

Targeting CTCFL/BORIS for the immunotherapy of cancer

Splice variants of human natural cytotoxicity receptors: novel innate immune checkpoints

Cystatin F as a regulator of immune cell cytotoxicity

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie